Author Correction: Sepsis-trained macrophages promote antitumoral tissue-resident T cells.

Autor: Broquet A; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.; CHU Nantes, INSERM, Nantes Université, Anesthesie Reanimation, CIC 1413, Nantes, France., Gourain V; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France., Goronflot T; CHU Nantes, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des Données, INSERM, Nantes Université, CIC 1413, Nantes, France., Le Mabecque V; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France., Sinha D; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France., Ashayeripanah M; Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Jacqueline C; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France., Martin P; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France., Davieau M; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.; CHU Nantes, INSERM, Nantes Université, Anesthesie Reanimation, CIC 1413, Nantes, France., Boutin L; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France., Poulain C; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.; CHU Nantes, INSERM, Nantes Université, Anesthesie Reanimation, CIC 1413, Nantes, France., Martin FP; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.; CHU Nantes, INSERM, Nantes Université, Anesthesie Reanimation, CIC 1413, Nantes, France., Fourgeux C; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France., Petrier M; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France., Cannevet M; CHU Nantes, INSERM, Nantes Université, Anesthesie Reanimation, CIC 1413, Nantes, France., Leclercq T; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France., Guillonneau M; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.; Olgram SAS, Bréhan, France., Chaumette T; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France., Laurent T; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France., Harly C; Nantes Université, INSERM, CRC2INA, Nantes, France., Scotet E; Nantes Université, INSERM, CRC2INA, Nantes, France., Legentil L; Ecole Nationale Supérieure de Chimie de Rennes, Université de Rennes, ISCR - UMR CNRS 6226, Rennes, France., Ferrières V; Ecole Nationale Supérieure de Chimie de Rennes, Université de Rennes, ISCR - UMR CNRS 6226, Rennes, France., Corgnac S; INSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Faculty de Médecine, Université Paris-Sud, Université Paris-Saclay, Villejuif, France., Mami-Chouaib F; INSERM UMR 1186, Integrative Tumour Immunology and Immunotherapy, Gustave Roussy, Faculty de Médecine, Université Paris-Sud, Université Paris-Saclay, Villejuif, France., Mosnier JF; CHU Nantes, Nantes Université, Anatomo-pathologie, Nantes, France., Mauduit N; CHU Nantes, Nantes Université, PMSI, Nantes, France., McWilliam HEG; Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia., Villadangos JA; Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia.; Department of Biochemistry and Pharmacology, Bio21 Molecular Science and Biotechnology Institute, The University of Melbourne, Parkville, Victoria, Australia., Gourraud PA; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.; CHU Nantes, Pôle Hospitalo-Universitaire 11: Santé Publique, Clinique des Données, INSERM, Nantes Université, CIC 1413, Nantes, France., Asehnoune K; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France.; CHU Nantes, INSERM, Nantes Université, Anesthesie Reanimation, CIC 1413, Nantes, France., Poschmann J; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France. jeremie.poschmann@univ-nantes.fr., Roquilly A; Nantes Université, CHU Nantes, INSERM, Center for Research in Transplantation and Translational Immunology UMR 1064, Nantes, France. antoine.roquilly@univ-nantes.Fr.; CHU Nantes, INSERM, Nantes Université, Anesthesie Reanimation, CIC 1413, Nantes, France. antoine.roquilly@univ-nantes.Fr.; Department of Microbiology and Immunology, The University of Melbourne, The Peter Doherty Institute for Infection and Immunity, Melbourne, Victoria, Australia. antoine.roquilly@univ-nantes.Fr.

Publikováno v: Nature immunology [Nat Immunol] 2024 Nov; Vol. 25 (11), pp. 2167.

Camelid-derived Tcell engagers harnessing human γδ T cells as promising antitumor immunotherapeutic agents.

Autor: Boutin L; Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France.; LabEx IGO 'Immunotherapy, Graft, Oncology', Nantes, France.; Sanofi, Large Molecule Research, Vitry-sur-Seine, France., Barjon C; Sanofi, Oncology, Vitry-sur-Seine, France., Chauvet M; Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France.; LabEx IGO 'Immunotherapy, Graft, Oncology', Nantes, France.; Sanofi, Oncology, Vitry-sur-Seine, France., Lafrance L; Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France.; LabEx IGO 'Immunotherapy, Graft, Oncology', Nantes, France., Senechal E; Sanofi, Large Molecule Research, Vitry-sur-Seine, France., Bourges D; Sanofi, Oncology, Vitry-sur-Seine, France., Vigne E; Sanofi, Large Molecule Research, Vitry-sur-Seine, France., Scotet E; Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France.; LabEx IGO 'Immunotherapy, Graft, Oncology', Nantes, France.

Publikováno v: European journal of immunology [Eur J Immunol] 2024 Aug; Vol. 54 (8), pp. e2350773. Date of Electronic Publication: 2024 May 28.

Anti-tumor efficacy of a combination therapy with PD-L1 targeted alpha therapy and adoptive cell transfer of PD-1 deficient melanoma-specific human T-lymphocytes

Autor: Marotte, L, Capitao, M, Deleine, C, Beauvais, T, Cadiou, G, Perrin, J, Chérel, M, Scotet, E, Guilloux, Y, Bruchertseifer, F, Morgenstern, A, Jarry, A, Gaschet, J, Labarrière, Nathalie

Publikováno v: OncoImmunology
OncoImmunology, Taylor & Francis, 2021, 10 (1), pp.e1940676. ⟨10.1080/2162402X.2021.1940676⟩
OncoImmunology, Vol 10, Iss 1 (2021)
OncoImmunology, 2021, 10 (1), pp.e1940676. ⟨10.1080/2162402X.2021.1940676⟩

International audience; The optimization of adoptive transfer approaches of anti-tumor T cells requires both the functional improvement of the injected T cells and the modulation of the tumor microenvironment, favoring the recruitment of these T cell

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::e8b45e949b2c8e65a0db281cb50f2979
https://www.hal.inserm.fr/inserm-03271847

The antitumor activity of human Vγ9Vδ2 T cells is impaired by TGF-β through significant phenotype, transcriptomic and metabolic changes.

Autor: Rafia C; Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France.; LabEx IGO 'Immunotherapy, Graft, Oncology', Nantes, France., Loizeau C; Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France.; LabEx IGO 'Immunotherapy, Graft, Oncology', Nantes, France., Renoult O; Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France.; LabEx IGO 'Immunotherapy, Graft, Oncology', Nantes, France., Harly C; Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France.; LabEx IGO 'Immunotherapy, Graft, Oncology', Nantes, France., Pecqueur C; Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France.; LabEx IGO 'Immunotherapy, Graft, Oncology', Nantes, France., Joalland N; Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France.; LabEx IGO 'Immunotherapy, Graft, Oncology', Nantes, France., Scotet E; Nantes Université, Inserm UMR 1307, CNRS UMR 6075, Université d'Angers, CRCI2NA, Nantes, France.; LabEx IGO 'Immunotherapy, Graft, Oncology', Nantes, France.

Publikováno v: Frontiers in immunology [Front Immunol] 2023 Jan 19; Vol. 13, pp. 1066336. Date of Electronic Publication: 2023 Jan 19 (Print Publication: 2022).

Development of ICT01, a first-in-class, anti-BTN3A antibody for activating Vγ9Vδ2 T cell-mediated antitumor immune response.

Autor: De Gassart A; ImCheck Therapeutics, 13009 Marseille, France., Le KS; ImCheck Therapeutics, 13009 Marseille, France., Brune P; ImCheck Therapeutics, 13009 Marseille, France., Agaugué S; ImCheck Therapeutics, 13009 Marseille, France., Sims J; Integrated Biologix GmbH, 4051 Basel, Switzerland., Goubard A; Aix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, TrGET preclinical platform, 13009 Marseille, France., Castellano R; Aix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, TrGET preclinical platform, 13009 Marseille, France., Joalland N; Université de Nantes, INSERM, CNRS, CRCINA, F-44000 Nantes, France.; LabEx IGO 'Immunotherapy, Graft, and Oncology,' Nantes F-44000, France., Scotet E; Université de Nantes, INSERM, CNRS, CRCINA, F-44000 Nantes, France.; LabEx IGO 'Immunotherapy, Graft, and Oncology,' Nantes F-44000, France., Collette Y; Aix Marseille University, CNRS, INSERM, Institut Paoli-Calmettes, CRCM, TrGET preclinical platform, 13009 Marseille, France., Valentin E; ImCheck Therapeutics, 13009 Marseille, France., Ghigo C; ImCheck Therapeutics, 13009 Marseille, France., Pasero C; ImCheck Therapeutics, 13009 Marseille, France., Colazet M; ImCheck Therapeutics, 13009 Marseille, France., Guillén J; ImCheck Therapeutics, 13009 Marseille, France., Cano CE; ImCheck Therapeutics, 13009 Marseille, France., Marabelle A; Département d'Innovation Thérapeutique et d'Essais Précoces (DITEP), Gustave Roussy, Université Paris-Saclay, 94805 Villejuif, France., De Bonno J; Division of Cancer Therapeutics, Institute of Cancer Research (ICR), London and Royal Marsden NHS Trust, Sutton SM2 5PT, UK., Hoet R; ImCheck Therapeutics, 13009 Marseille, France.; Biopharmaceutics, Dept. Pathology, University of Maastricht, 6200 MD Netherlands., Truneh A; ImCheck Therapeutics, 13009 Marseille, France., Olive D; Centre de Recherche en Cancérologie de Marseille (CRCM), Inserm, U1068, CNRS, UMR7258, Institut Paoli-Calmettes, Aix-Marseille University, UM 105, 13009 Marseille, France., Frohna P; ImCheck Therapeutics, 13009 Marseille, France.

Publikováno v: Science translational medicine [Sci Transl Med] 2021 Oct 20; Vol. 13 (616), pp. eabj0835. Date of Electronic Publication: 2021 Oct 20.